Investor Presentaiton

India Robust India business performance India quarterly Sales (INR bn) 13.7 13.3 12.9 12.9 Q1FY22 (42% YOY QoQ 27.3% 27.2% LUPIN Consistently outpacing chronic market growth 5 Year CAGR % Lupin Rank¹ 16.4 MAT MAT Therapy Market Lupin Jun-16 Jun-21 Acute Chronic 9% 6% 13 15 11% 15% 5 4 Cardiac 11% 12% 3 3 Anti-diabetics 13% 21% 5 3 Respiratory 9% 14% 4 2 Q1 FY21 Q2 FY21 Q3 FY21 Q4 FY21 Q1 FY22 6th rank in the IPM¹ • 64.5% Chronic contribution¹; Our chronic segment grew 22.6% against 19.4% chronic market growth in Q1 FY222 Branded formulations grew 30.9% YoY in Q1FY22 • For Lupin, Cardiac, Respiratory, Anti Infectives and Gl witnessed strong growth ~7,700 domestic sales force strength; PCPM tracking at INR 0.92 mn per month in Q1FY22 Strong focus on building brands BRANDS • RANK (MAT Jun'21) GLUCONORM-G 40 HUMINSULIN 85 2 brands in Top BUDAMATE 103 100 GIBTULIO 160 · CIDMUS 169 10 brands in Top 300 ONDERO 193 TONACT 216 IVABRAD 236 RABLET-D 288 AJADUO 289 Note: 1. IQVIA MAT Jun-21; 2. IQVIA 08

View entire presentation